Analyst firms · Oppenheimer · RLAY
Oppenheimer RLAY price target and rating history
Relay Therapeutics Inc. (RLAY) · Health Care
Oppenheimer rates Relay Therapeutics Inc. (RLAY) Outperform with a $14 price target, as of its latest action on Jan 26, 2026. It has published 3 rating actions on RLAY since February 2023, including 1 upgrade and 1 downgrade. Across 3 firms with a RLAY price target in the last 12 months, the median target is $14. Oppenheimer's target matches it.
- Current rating
- Outperform
- Price target
- $14
- Median target, all firms
- $14
- Actions on RLAY
- 3
Oppenheimer price target on RLAY
Every Oppenheimer rating on RLAY
- Jan 26, 2026
- Sep 10, 2024
- Feb 3, 2023
How other firms rate RLAY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Canaccord Genuity | Buy | $29 | Jul 16, 2026 |
| Oppenheimer | Outperform | $14 | Jan 26, 2026 |
| Wells Fargo | Overweight | $13 | Dec 12, 2025 |
Questions about Oppenheimer and RLAY
- What is Oppenheimer's price target for RLAY?
- Oppenheimer's latest stated price target for Relay Therapeutics Inc. (RLAY) is $14, from its action on Jan 26, 2026.
- What is Oppenheimer's rating on RLAY?
- Oppenheimer rates RLAY Outperform, a bullish rating, as of Jan 26, 2026.
- When did Oppenheimer last change its view on RLAY?
- On Jan 26, 2026, Oppenheimer upgrades to Outperform from Perform, price target $14.
- How does Oppenheimer's RLAY target compare with other analysts?
- Across 3 firms with a RLAY price target in the last 12 months, the median target is $14. Oppenheimer's target matches it.
More RLAY rating histories
All Oppenheimer ratingsRLAY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.